Effect of Ubiquinone Lactic Acid Levels and 6 Minute Walking Test in Patients Chronic Obstructive Pulmonary Disease Stable Category B and D


Ahmad Rifani, Arief Bakhtiar, Muhammad Amin
Departemen Pulmonologi dan Kedokteran Respirasi Fakultas Kedokteran Universitas Airlangga, RSUD Dr. Soetomo, Surabaya


Background: Chronic obstructive pulmonary disease known as chronic inflammatory disease that do not occur locally in the lung but also a systemic effect, including peripheral muscle weakness and increased lactic acid. Ubiquinone contained in the mitochondria and plays an important role in aerobic energy production and also have antioxidant effects. This study to determine the effect of ubiquinone on levels of lactic acid and 6 minute walking test (6 MWT) exercise tolerance of COPD patients with stable category B and D.
Methods: This study is an experimental study with double-blind randomized controlled. The subjects of this study are patients with stable COPD category B and Dwhich at the outpatient Pulmonary clinic of Dr.Soetomo Hospital and meet the inclusion and exclusion criteria. Patients who meet the selection criteria are divided into 2 groups, ubiquinone and placebo for 8 weeks and patients continue to use drugs regularly. All patients measured blood levels of lactic acid, the 6-minute walk test, spirometry before and after administration of ubiquinone or placebo.
Results: A total 32 subjects were divided into 16 patients in ubiquinone groups and 16 patients in control groups. There were no significant differences between the two groups in gender, degree of COPD and BMI. Lactic acid levels in the treatment group decreased significantly compared with the control (4.619 ± 0.429 to be 3.131 ± 0.583 in ubiquinone group, 4.544 ± 0.383 to be 4.675 ± 0.409 in control group; p <0.017). Pulmonary function tests were not statistically significant in both groups. On the 6-minute walking distance increased in the treatment group compared with the control group (296,81 ± 61,123 to be 354,38±53,131 in ubiquinone group and 329,06 ± 53,610 to be 319,06±44,990 in control group;p<0.014).
Conclusion: Ubiquinone administration has favorable effect on the energy production of muscle and lower lactic acid levels in patients with stable COPD category B and D. (J Respir Indo. 2017; 37: 15-22)
Keywords: ubiquinon, stable COPD category B and D, lactic acid levels, 6 MWT, quality of life

Click here for full paper (PDF)